EBS

8.77

1.68% -0.15

Dopo l'orario di chiusura: 8.77

Emergent Biosolutions Inc (EBS)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Forum Previsione

Precedente Chiudi:

$8.92

Aprire:

$8.9

Volume 24 ore:

1.72M

Relative Volume:

1.88

Capitalizzazione di mercato:

$460.60M

Reddito:

$1.02B

Utile/perdita netta:

$-757.20M

Rapporto P/E:

-0.5942

EPS:

-14.76

Flusso di cassa netto:

$-257.90M

1 W Prestazione:

-20.35%

1M Prestazione:

-23.14%

6M Prestazione:

+14.94%

1 anno Prestazione:

+37.25%

Intervallo 1D:

$8.665

$9.025

Intervallo di 1 settimana:

$7.81

$11.46

Portata 52W:

$4.02

$14.06

Emergent Biosolutions Inc Stock (EBS) Company Profile

Nome

Emergent Biosolutions Inc

Settore

Healthcare (1106)

Industria

Drug Manufacturers - Specialty & Generic (82)

Telefono

240-631-3200

Indirizzo

300 PROFESSIONAL DR, GAITHERSBURG, MD

Dipendente

900

Cinguettio

@emergentbiosolu

Prossima data di guadagno

2025-03-03

Ultimi documenti SEC

EBS's Discussions on Twitter

Compare EBS vs TAK, ZTS, HLN, TEVA, UTHR

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
EBS Emergent Biosolutions Inc	8.77	468.48M	1.02B	-757.20M	-257.90M	-14.76
TAK Takeda Pharmaceutical Co Adr	18.22	57.12B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	125.96	53.16B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	10.47	47.25B	14.54B	2.22B	2.58B	0.4879
TEVA Teva Pharmaceutical Industries Ltd Adr	32.91	37.59B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	490.21	21.85B	3.13B	1.27B	1.12B	26.39

Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2024-12-30	Iniziato	H.C. Wainwright	Buy
2024-08-22	Iniziato	Rodman & Renshaw	Buy
2024-03-07	Aggiornamento	The Benchmark Company	Hold → Buy
2023-11-20	Ripresa	JP Morgan	Underweight
2023-08-29	Downgrade	The Benchmark Company	Buy → Hold
2023-04-10	Aggiornamento	The Benchmark Company	Hold → Buy
2023-03-17	Downgrade	JP Morgan	Neutral → Underweight
2022-11-10	Downgrade	The Benchmark Company	Buy → Hold
2022-04-29	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2022-01-20	Aggiornamento	The Benchmark Company	Hold → Buy
2021-11-08	Downgrade	The Benchmark Company	Buy → Hold
2021-05-05	Downgrade	Argus	Buy → Hold
2021-04-07	Iniziato	The Benchmark Company	Buy
2021-02-24	Aggiornamento	Chardan Capital Markets	Neutral → Buy
2021-02-19	Downgrade	Chardan Capital Markets	Buy → Neutral
2021-01-08	Downgrade	Wells Fargo	Overweight → Equal Weight
2020-09-14	Ripresa	JP Morgan	Neutral
2020-07-31	Reiterato	Chardan Capital Markets	Buy
2019-09-12	Iniziato	Guggenheim	Buy
2019-09-04	Aggiornamento	Wells Fargo	Market Perform → Outperform
2018-11-02	Aggiornamento	Goldman	Neutral → Buy
2018-08-03	Reiterato	Chardan Capital Markets	Buy
2018-06-13	Iniziato	Argus	Buy
2018-04-25	Downgrade	Wells Fargo	Outperform → Market Perform
2018-01-24	Iniziato	Goldman	Neutral
2018-01-16	Reiterato	Chardan Capital Markets	Buy
2016-06-28	Reiterato	Singular Research	Buy
2016-04-15	Iniziato	Chardan Capital Markets	Buy
2016-03-28	Iniziato	Singular Research	Buy
2016-02-19	Iniziato	Wells Fargo	Outperform
2014-05-15	Iniziato	Summer Street Research	Buy
2011-05-31	Reiterato	WBB Securities	Strong Buy
2011-01-10	Reiterato	Wedbush	Outperform
2010-11-05	Reiterato	Wedbush	Outperform
2010-08-18	Aggiornamento	WBB Securities	Buy → Strong Buy
2010-08-06	Reiterato	Caris & Company	Buy

Mostra tutto

Emergent Biosolutions Inc Borsa (EBS) Ultime notizie

Mar 03, 2026

EBS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

Mar 03, 2026

Emergent BioSolutions (EBS) SVP reports 116-share tax-withholding disposition - Stock Titan

Mar 03, 2026

Emergent BioSolutions (EBS) CFO logs 683-share tax-withholding disposition - Stock Titan

Mar 03, 2026

Emergent BioSolutions (EBS) EVP has 313 shares withheld for RSU taxes - Stock Titan

Mar 03, 2026

Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors - The Globe and Mail

Mar 03, 2026

Emergent BioSolutions announces appointment of John D. Fowler, Jr. to board of directors - marketscreener.com

Mar 03, 2026

Emergent BioSolutions Adds Independent Director Amid Turnaround Efforts - TipRanks

Mar 03, 2026

Emergent BioSolutions appoints John D. Fowler, Jr. as director and Audit and Finance Committee member - TradingView

Mar 03, 2026

John Fowler joins Emergent BioSolutions (NYSE: EBS) board, Audit role - Stock Titan

Mar 03, 2026

Emergent Biosolutions Announces Appointment Of John D. Fowler, Jr. To Board Of Directors - TradingView

Mar 03, 2026

Mar 02, 2026

Emergent Biosolutions secures new contracts with Public Health Agency of Canada and Defence Department - Traders Union

Mar 02, 2026

Mar 01, 2026

Aug Levels: Is Emergent BioSolutions Inc stock showing strong momentumPortfolio Performance Summary & Accurate Intraday Trading Signals - baoquankhu1.vn

Mar 01, 2026

Feb 28, 2026

Q4 2025 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus

Feb 28, 2026

Emergent BioSolutions Earnings: Revenue, Margins And GAAP Losses Paint Mixed Picture (EBS) - Seeking Alpha

Feb 28, 2026

Emergent BioSolutions (EBS) Stock Falls on Disappointing Revenue Guidance - GuruFocus

Feb 27, 2026

Emergent BioSolutions authorizes $50M stock buyback program By Investing.com - Investing.com India

Feb 27, 2026

Why Did Emergent Biosolutions Stock Tumble 20% After-Hours Today? - Stocktwits

Feb 27, 2026